CompanyPrivateWaltham, MA

Checkpoint Therapeutics, Inc

Checkpoint Therapeutics develops immunotherapy and targeted oncology treatments for solid tumors.

SEC EDGAR ClinicalTrials.gov

10-QAug 13Latest SEC filing, period to Jun 30

Form DJul 10Private placement

November 2026

FDA approves cosibelimab-ipdl for advanced skin cancer

Nov 6Regulatory decisionCheckpoint Therapeutics, Inc cosibelimab-ipdl